top of page

  • Founded Shamrock Structures as a drug discovery services company offering protein crystallography, medicinal chemistry and cell biology services.

  • Founded Advanced Life Sciences (ADLS) as an anti-infective and anti-cancer drug discovery & development company.

  • Led the negotiation for license to acquire Phase 3 antibiotic, Restanza, from Abbott Laboratories.

  • Completed $35 Million IPO for ADLS.

  • Completed two Private Investments in a Public Equity (PIPEs) of $36 Million and $20 Million each, for ADLS.

  • Secured $4 Million award with the DTRA for biodefense contract to develop Restanza in plague, tularemia and Burkholderia pseudomallei.

  • Negotiated Standby Equity Distribution Agreement and raised $15 million through stock sales for ADLS.

  • Negotiated a development and commercialization agreement for the Asia Pacific region with Wyeth for Restanza.

  • Led the submission of New Drug Application (NDA) to FDA for Restanza.

  • Successfully lobbied BARDA to adjust Broad Agency Announcement rules to reflect FDA requirements, including clinical development of antibiotics for commercial indications to support biodefense approval.

  • Met with FDA in over a dozen face-to-face meetings to establish regulatory pathway in CABP and biodefense indications including anthrax, plague, tularemia and Burkholderia pseudomallei.

  • Successfully finalized a special protocol assessment (SPA) with the FDA for novel oral antibiotic, Restanza™ (cethromycin), for treatment of community acquired bacterial pneumonia (CABP).

  • Founded MediChem Life Sciences (MCLS) as one of the first medicinal chemistry contract research organizations.

  • Completed a $35 Million private equity and debt financing for MCLS.

  • Formed Sarawak MediChem Pharmaceuticals (SMP), a joint venture with the Government of Sarawak, Malaysia, and recruited $20 million investment from the Sarawak Government to develop calanolide A, a natural product found in the Malaysian rainforest as a treatment for HIV/AIDS.

  • Managed MCLS acquisition and integration of two biotechnology companies, ThermoGen and Emerald BioStructures.

  • Completed $54 Million IPO of MCLS.

  • Built a 110,000 square foot laboratory and office building in Woodridge, IL to house MCLS operations.

  • Completed sale of MCLS to DeCODE Genetics for $84 Million.

bottom of page